Affiliation:
1. Department of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ, USA
2. Princeton School of Public and International Affairs, Princeton University, Princeton, NJ, USA
Abstract
The evolution of SARS-CoV-2 virulence, or lethality, threatens to exacerbate the burden of COVID-19 on society. How might COVID-19 vaccines alter selection for increased SARS-CoV-2 virulence? Framing current evidence surrounding SARS-CoV-2 biology and COVID-19 vaccines in the context of evolutionary theory indicates that prospects for virulence evolution remain uncertain. However, differential effects of vaccinal immunity on transmission and disease severity between respiratory compartments could select for increased virulence. To bound expectations for this outcome, we analyse an evo-epidemiological model. Synthesizing model predictions with vaccine efficacy data, we conclude that while vaccine-driven virulence remains a theoretical possibility, the risk is low if vaccines provide sustained robust protection against infection. Furthermore, we found that any increases in transmission concomitant with increases in virulence would be unlikely to threaten prospects for herd immunity in a highly immunized population. Given that virulence evolution would nevertheless impact unvaccinated individuals and populations with low vaccination rates, it is important to achieve high vaccination rates worldwide and ensure that vaccinal immunity provides robust protection against both infection and disease, potentially through the use of booster doses.
Funder
National Science Foundation
Reference80 articles.
1. World Health Organization. 2021 COVID-19 Weekly Epidemiological Update 63. See https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19-26-october-2021.
2. World Bank. 2020 Global economic prospects June 2020 . Washington DC: World Bank. (doi:10.1596/978-1-4648-1553-9)
3. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
4. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
5. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献